Company news
Hunan Nucien Pharmaceutical Co. Ltd. Class A (SSE:688189) news
Hunan Nucien Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Sep 23, 2026: "Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Resolutions…
Press releases & updates
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 22, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Election of New Board of Directors
September 4, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Shareholding Reduction Plan of Shareholder
September 2, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Progress of the Transfer of Certain Accounts Receivable and Related Party Transactions
August 31, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 30, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Hunan Jurisdiction and Semi-annual Performance Briefing
August 25, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Appointment of General Manager
August 21, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on the Receipt of Warning Letters by the Company and Relevant Responsible Persons
August 13, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Reduction of Registered Capital, Amendment of the Articles of Association, and Completion of Industrial and Commercial Registration Changes
August 10, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 15, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
July 14, 2026
"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Implementing Cancellation of Repurchased Shares and Share Changes
July 8, 2026
Announcement on Receipt of Drug Registration Acceptance Notice
June 22, 2026
Announcement on Progress in the Strategic Restructuring of Controlling Shareholders
June 17, 2026
Announcement on Obtaining Drug Registration Certificate for Levosalbutamol Hydrochloride Nebuliser Solution
June 16, 2026
Announcement on Voluntary Disclosure of Phase III Clinical Trial of Peramivir Inhalation Solution Reaching Prespecified Primary Endpoint
June 11, 2026
Announcement on Receiving the Prior Notice of Administrative Penalty
June 9, 2026
Announcement on Progress in Transfer of Partial Accounts Receivable and Related Party Transactions
June 1, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 22, 2026
Indicative Announcement on the Controlling Shareholder's Planning of Strategic Restructuring
May 14, 2026
Announcement on Changing Purpose of Repurchased Shares Canceling and Reducing Registered Capital, and Amending the "Articles of Association"
April 29, 2026
Announcement on Resignation of Core Technical Personnel
April 24, 2026
Announcement on Progress in Public Listing and Transfer of Partial Accounts Receivable
April 15, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
April 1, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 11, 2026
Announcement on Expected Loss in Performance for 2025
January 30, 2026
Announcement on By-electing an Independent Director and Adjusting Members of Partial Special Committees
January 26, 2026
Announcement on Resignation of Independent Director
January 4, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 26, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
December 10, 2025
Report for Q3 2025
October 30, 2025
Announcement on Early Returning of Raised Funds Temporarily Used for Supplementing Current Capital
October 21, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
October 10, 2025
Announcement on Serious Abnormal Fluctuations in Stock Trading
October 9, 2025
Announcement on Receiving Notice of Litigation Filing from China Securities Regulatory Commission
September 30, 2025
Announcement on Progress in Planning Major Asset Restructuring
September 26, 2025
Announcement on Shareholding Reduction Plan for Shareholders
September 24, 2025
Announcement on Resolutions of the 16th Meeting of the 2nd Board of Supervisors
September 22, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Hunan Jurisdiction and Semi-annual Performance Briefing
September 12, 2025
Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase
August 29, 2025
Special Report on Semi-annual Deposit and Use of Raised Funds in 2025
August 28, 2025
Indicative Announcement on Planning Major Asset Restructuring and Signing the "Agreement of Intention for Acquisition"
August 26, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 30, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 13, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
May 30, 2025
Announcement on Using Extra Raised Funds to Permanently Supplement Current Capital
May 23, 2025
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders without Sales Limit Concerning Shares Repurchase
May 7, 2025
Announcement on Proposed Cancellation of Subsidiary
April 29, 2025